PDCD1 and malignant colon neoplasm: The rationale is based on the observation of systemic tumor responses (abscopal effect) in metastatic, MSS pancreatic or colon cancer—i.e., tumors notoriously resistant to immune checkpoint inhibitors—when combining PD-1/CTLA-4 inhibitors with radiotherapy [76].